Literature DB >> 19467619

NOD2-associated diseases: Bridging innate immunity and autoinflammation.

Arturo Borzutzky1, Ari Fried, Janet Chou, Francisco A Bonilla, Susan Kim, Fatma Dedeoglu.   

Abstract

NOD2 is an intracellular microbial sensor of the innate immune system that can act as a potent activator and regulator of inflammation. Mutations in the gene encoding NOD2 in humans have been associated with Crohn's disease (CD), Blau syndrome (BS), and early onset sarcoidosis (EOS). These diseases have in common features of dysregulated inflammation, but have very distinct phenotypes, which have been hypothesized to result from either loss-of-function (CD) or gain-of-function (BS/EOS) mutations. Here we describe an infant with early onset sarcoidosis who presented with systemic inflammation and disseminated granulomatous disease, including the triad of granulomatous arthritis, uveitis and dermatitis, as well as unusual gastrointestinal tract granulomas. The patient had a susceptibility polymorphism of NOD2 previously described in CD, but not in BS or EOS. We discuss the complex role of NOD2 in innate immunity to microbes and the clinical consequences of disturbances in this system. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467619     DOI: 10.1016/j.clim.2009.05.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  25 in total

Review 1.  New insights into gastrointestinal and hepatic granulomatous disorders.

Authors:  Majid A Almadi; Abdulrahman M Aljebreen; Faisal M Sanai; Victoria Marcus; Ebtissam S Almeghaiseeb; Subrata Ghosh
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-05       Impact factor: 46.802

2.  Comorbidities of hidradenitis suppurativa (acne inversa).

Authors:  Sabine Fimmel; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2010-01

Review 3.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

4.  ASC-dependent RIP2 kinase regulates reduced PGE2 production in chronic periodontitis.

Authors:  D J Taxman; Y Lei; S Zhang; E Holley-Guthrie; S Offenbacher; J P-Y Ting
Journal:  J Dent Res       Date:  2012-07-24       Impact factor: 6.116

5.  The molecular chaperone HSP70 binds to and stabilizes NOD2, an important protein involved in Crohn disease.

Authors:  Vishnu Mohanan; Catherine Leimkuhler Grimes
Journal:  J Biol Chem       Date:  2014-04-30       Impact factor: 5.157

Review 6.  A Chinese case series of Yao syndrome and literature review.

Authors:  Xinglin Yang; Di Wu; Ji Li; Min Shen; Wen Zhang
Journal:  Clin Rheumatol       Date:  2018-08-29       Impact factor: 2.980

Review 7.  New insights into the pathogenesis and treatment of necrotizing enterocolitis: Toll-like receptors and beyond.

Authors:  Amin Afrazi; Chhinder P Sodhi; Ward Richardson; Matthew Neal; Misty Good; Richard Siggers; David J Hackam
Journal:  Pediatr Res       Date:  2011-03       Impact factor: 3.756

Review 8.  Potential roles of nucleotide-binding oligomerization domain 2 in the pathogenesis of systemic lupus erythematosus.

Authors:  Jing Li; Song Wu; Ming-Rui Wang; Ting-Ting Wang; Bai-Kun Li; Ji-Min Zhu
Journal:  Rheumatol Int       Date:  2014-03-06       Impact factor: 2.631

9.  Unique Variant of NOD2 Pediatric Granulomatous Arthritis With Severe 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia and Generalized Osteosclerosis.

Authors:  Michael P Whyte; Emilina Lim; William H McAlister; Gary S Gottesman; Lien Trinh; Deborah J Veis; Vinieth N Bijanki; Matthew G Boden; Angela Nenninger; Steven Mumm; David Buchbinder
Journal:  J Bone Miner Res       Date:  2018-07-30       Impact factor: 6.741

10.  Blau Syndrome and Early-Onset Sarcoidosis: A Six Case Series and Review of the Literature.

Authors:  Ayşenur PaÇ Kisaarslan; Betül SÖzerİ; Nihal Şahİn; Sümeyra Özdemİr ÇİÇek; Zübeyde GÜndÜz; Erkan Demİrkaya; Afig Berdelİ; Serdal Sadet Özcan; Hakan PorazoĞlu; Ruhan DÜŞÜnsel
Journal:  Arch Rheumatol       Date:  2019-11-06       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.